Molecularly targeted agents in myelodysplastic syndrome
The Vera and Joseph Dresner Foundation granted The Cleveland Clinic Foundation a $250,000 grant for early career investigator Dr. Valeria Visconte.
The researchers believe that repairing the defective function caused by mutations will be the strategy of the future to treat MDS. The goal of their project is to further improve a novel chemical they have identified as a potential drug and test whether it will be effective as a future therapy for MDS patients with SF3B1 mutations.
Learn more about The Cleveland Clinic Foundation